Key clinical point: First-line lorlatinib significantly prolonged progression-free survival when compared with crizotinib in advanced ALK-positive non–small cell lung cancer.
Major finding: The median progression-free survival was 9.3 months in the crizotinib arm and was not reached in the lorlatinib arm (hazard ratio, 0.21; P < .001).
Study details: A phase 3 trial of 296 patients, 149 randomized to lorlatinib at 100 mg daily and 147 randomized to crizotinib at 250 mg twice daily.
Disclosures: Pfizer, the maker of both lorlatinib and crizotinib, funded the trial. The presenter disclosed ties to Pfizer.
Solomon B et al. ESMO 2020, Abstract LBA2.